Fig. 2From: Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case reportMRI showed pseudo-progression of the primary tumor. A and B MRI in January 2021. C and D MRI in July 2021. Abbreviations: MRI, magnetic resonance imagingBack to article page